Regeneron

MDR Article 117: What It Means — And How We Help You Get Ahead

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs

How to Reduce Notified Body Review Cycles Through Better Clinical Documentation

The Great Convergence — Why 2026 is the Year Regulatory “Records” Die

Raw Material Compliance in Pharmaceuticals: Naming, Pharmacopeial Grade, and Safety Requirements

EMA Upgrades xEVMPD Web Interface